» Articles » PMID: 36033957

Astragaloside IV Regulates Autophagy-mediated Proliferation and Apoptosis in a Rat Model of PCOS by Activating the PPARγ Pathway

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Astragaloside IV (AS-IV) is a bioactive saponin with a wide range of pharmacological effects. This study was aimed at investigating its potential effect on polycystic ovary syndrome (PCOS).

Materials And Methods: Female Sprague-Dawley rats were randomly divided into five groups (control, PCOS, PCOS+AS-IV 20 mg/kg, PCOS+AS-IV 40 mg/kg, and PCOS+AS-IV 80 mg/kg). The pathological injury level of rat ovary was observed with hematoxylin-eosin (H&E) staining; enzyme-linked immunosorbent assay (ELISA) kit was utilized to measure the levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone in rat serum; western blot detected autophagy-associated or peroxisome proliferator-activated receptor γ (PPARγ) pathway-related protein expression; immunofluorescence was performed to observe LC3 level in rat ovarian tissue. After co-treatment with AS-IV and PPARγ inhibitor, the proliferation in ovarian granulosa cell line KGN was examined employing cell counting kit-8 (CCK-8), EdU staining, and colony formation; cell apoptosis was observed with TdT-mediated dUTP nick-end labeling (TUNEL); apoptosis-related protein expression was assayed by western blot.

Results: Treatment with AS-IV inhibited the ovarian pathological damage in PCOS rats. It also promoted the level of autophagy and activated PPARγ signaling in the rat PCOS model. In KGN cells, the level of autophagy and expression of PPARγ-related proteins were also elevated by AS-IV treatment. Furthermore, AS-IV facilitated autophagy, thus inhibiting KGN cell proliferation and promoting its apoptosis, through activating the PPARγ signaling pathway.

Conclusion: AS-IV-activated PPARγ inhibits proliferation and promotes the apoptosis of ovarian granulosa cells, enhancing ovarian function in rats with PCOS.

Citing Articles

Natural compounds in the management of polycystic ovary syndrome: a comprehensive review of hormonal regulation and therapeutic potential.

Yuan J, Li Z, Yu Y, Wang X, Zhao Y Front Nutr. 2025; 12:1520695.

PMID: 40008316 PMC: 11850276. DOI: 10.3389/fnut.2025.1520695.


The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions.

Kounatidis D, Vallianou N, Rebelos E, Kouveletsou M, Kontrafouri P, Eleftheriadou I Curr Obes Rep. 2025; 14(1):19.

PMID: 39934485 DOI: 10.1007/s13679-025-00612-4.


Role of the AMP-Activated Protein Kinase in the Pathogenesis of Polycystic Ovary Syndrome.

Jalil A, Zair M, Hanthal Z, Naser S, Aslandook T, Abosaooda M Indian J Clin Biochem. 2024; 39(4):450-458.

PMID: 39346714 PMC: 11436500. DOI: 10.1007/s12291-023-01139-y.


Mechanism of Astragaloside IV in Treatment of Renal Tubulointerstitial Fibrosis.

Wang X, Luan J, Guo Z Chin J Integr Med. 2024; .

PMID: 38850482 DOI: 10.1007/s11655-024-3805-6.


Exosomes from adipose-derived stem cells alleviate premature ovarian failure via blockage of autophagy and AMPK/mTOR pathway.

Ren Y, He J, Wang X, Liang H, Ma Y PeerJ. 2023; 11:e16517.

PMID: 38107591 PMC: 10725676. DOI: 10.7717/peerj.16517.


References
1.
Wang X, Gao Y, Tian N, Wang T, Shi Y, Xu J . Astragaloside IV inhibits glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT-NF-κB p65 axis. Sci Rep. 2019; 9(1):323. PMC: 6344540. DOI: 10.1038/s41598-018-36911-1. View

2.
Legro R . Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med. 2012; 30(6):496-506. PMC: 3649566. DOI: 10.1055/s-0032-1328878. View

3.
Ren S, Zhang H, Mu Y, Sun M, Liu P . Pharmacological effects of Astragaloside IV: a literature review. J Tradit Chin Med. 2013; 33(3):413-6. DOI: 10.1016/s0254-6272(13)60189-2. View

4.
Wojciechowska A, Osowski A, Jozwik M, Gorecki R, Rynkiewicz A, Wojtkiewicz J . Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS. Int J Mol Sci. 2019; 20(22). PMC: 6888190. DOI: 10.3390/ijms20225787. View

5.
Khattak M, Sultana N, Usman R, Khattak U, Zafar U, Salman H . Luteinizing Hormone To Follicle Stimulating Hormone Ratio In Patients With Polycystic Ovary Syndrome. J Ayub Med Coll Abbottabad. 2020; 32(2):255-258. View